This bill, titled “An Act relative to modern family building,” expands insurance coverage and related state health program benefits for fertility diagnostic care and fertility treatment across several Massachusetts insurance systems, including Group Insurance Commission coverage for state employees, MassHealth, and private insurance regulated under chapters 175, 176A, 176B, and 176G. It defines fertility diagnostic care, fertility treatment, and infertility broadly, and requires coverage for services such as IVF, oocyte retrievals, embryo transfers, intrauterine insemination, and intracervical insemination. The bill also extends coverage for storage of cryopreserved reproductive tissue until age 35 or for at least five years, whichever is later.
The bill further prohibits insurers from imposing certain restrictions that differ from those applied to other medical services, including different cost-sharing, medication limits, or denials based on use of third-party fertility services such as gestational carriers, surrogates, or donated genetic material. It also bars conditions such as prior treatment requirements, age, sexual orientation, gender identity, or familial status from being used to deny benefits under the Group Insurance Commission section. For MassHealth, the bill requires coverage for fertility diagnostic care, ovulation-enhancing drugs, related monitoring, and intrauterine insemination, including at least three cycles of ovulation-enhancing medication treatment over a recipient’s lifetime.
In addition to insurance mandates, the bill directs the Bureau of Health Professions Licensure to develop a professional training module on LGBTQ family-building resources and services for medical and clinical licensing boards, with the module counting for continuing professional development credits. It also requires the Office of Health Equity to study the affordability, accessibility, and practicality of family-building resources for LGBTQ individuals and couples, including rural access, provider training, out-of-pocket costs, donor policies, and best practices, and to report recommendations by December 31, 2026.
Because the bill would amend multiple chapters of the General Laws, it would materially expand mandated fertility-related benefits in both public and private coverage and create new training and study obligations for state agencies. It would affect insurers, state employee health coverage, MassHealth, health maintenance contracts, and medical providers who offer reproductive services, while also setting a more explicit statewide standard for fertility care access and nondiscrimination in coverage.
No committee transcripts or recorded votes were provided, so there is no documented legislative debate or vote history to gauge sentiment. Based on the bill text alone, the measure appears broadly supportive of expanded reproductive health access and LGBTQ-inclusive family-building, with the main likely points of contention being insurance cost impacts, the scope of mandated benefits, limits on insurer flexibility, and coverage of services involving surrogacy, donor gametes, and embryo storage.
The bill would amend chapters 32A, 118E, 175, 176A, 176B, and 176G of the General Laws to require fertility diagnostic care and fertility treatment coverage in public employee health plans, MassHealth, and most private health insurance products that include pregnancy-related benefits. It also expands or clarifies coverage for cryopreservation storage, imposes nondiscrimination and parity rules for fertility-related cost-sharing and exclusions, and creates new state agency duties for LGBTQ family-building training and a health equity study. These changes would directly affect insurers, public programs, licensed providers, and individuals seeking fertility services in Massachusetts.
No committee discussion or voting record was provided, so there is no formal legislative sentiment available from the materials. The bill text suggests a generally supportive posture toward fertility access, reproductive autonomy, and LGBTQ family-building, with an emphasis on expanding benefits and reducing barriers. The absence of recorded opposition in the provided materials means any controversy can only be inferred from the policy design rather than from stated debate.
The most likely points of contention are the cost and scope of the insurance mandates, especially the requirement to cover multiple oocyte retrievals, unlimited embryo transfers, and unlimited insemination cycles. Insurers and employers may object to the prohibition on different deductibles, copayments, coinsurance, or benefit maximums for fertility care, as well as the ban on denying coverage because a patient used surrogacy, gestational carriers, or donor genetic material. Another possible area of debate is the bill’s explicit inclusion of LGBTQ family-building training and nondiscrimination protections, which supporters would view as access measures but critics might characterize as beyond traditional infertility coverage. Coverage of cryopreservation storage until age 35 or five years, whichever is later, and the breadth of the infertility definition may also raise concerns about utilization and program costs.